Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/17/2010

as well as matched tumor samples from head and neck cancer patients not treated with Multikine. The pathologists who participated in this study were blinded to the study and to the patients' clinical outcome.  The results were so impressive that we were able to present the pathology tumor data at ASCO (American Society of Clinical Oncology) and have them published in the very prestigious peer-reviewed Journal of Clinical Oncology.  The promising overall survival data were presented in an oral presentation at the International Conference of Oral Oncology, Amsterdam, 2007 and were published in the peer-reviewed Journal of Oral Oncology.  

The pathology data showed clear clinical benefit to the Multikine-treated patients and suggested that overall patient survival should be improved with Multikine administration.  The longer-term follow-up of the Multikine-treated patients showed that overall survival indeed was improved in these patients.  To avoid any bias, the Multikine survival data in the Phase II trial was compared to the results of all peer reviewed published data available at that time (39 publications).  As time progressed and more publications became available, we updated this comparison and included all of the more recently published peer-reviewed data from these publications (a total of 55 publications).  Our findings of the impact of Multikine administration on the overall survival benefit for these patients still held true.

The safety and efficacy data for Multikine were reviewed by different regulatory agencies, including the US Food and Drug Administration (FDA), prior to giving CEL-SCI clearance to proceed with a global Phase III for Multikine in head and neck cancer.  The open-label, randomized, controlled Phase III study of Multikine in patients with head and neck cancer is designed to demonstrate that Multikine administration to these patients yields
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... COLUMBUS, Ohio , Aug. 19, 2014 ... Ohio medical device company, announced today that ... FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan ... Corporation is also the exclusive distributor for Karl Storz ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... ANGELES, Jan. 13, 2011 UBM Canon and ... webinar to its webcast series on The Fundamentals of ... on Advanced Assay Technologies and Development Methods ... experts in the industry.   (Logo:   ...
... 13, 2011 CareGiver remote instrument support has expanded ... Medical System, Inc. ("VMSI") is the leading innovator in ... 5 years of success on the SYMPHONY H&E slide ... BenchMark ULTRA, strengthening the integration of the SYMPHONY and ...
Cached Medicine Technology:Advanced Assay Technologies and Development Methods 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... 20, 2014 One Call Alert expands its ... of ResCube, a fully-mobile wearable device that connects customers to ... button, 24 hours a day, 365 days a year. , ... cross country. It operates on the T-Mobile nationwide network like ... in to work. , Like with the other One Call ...
(Date:8/20/2014)... at the Universities of Manchester and Auckland suggest that both ... mechanism. , The findings, published today in the ... or type-1 diabetes and type-2 diabetes are both caused by ... , The results, based on 20 years, work ... both be slowed down and potentially reversed by medicines that ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
(Date:8/20/2014)... 20, 2014 Today, Zane Benefits, the ... open enrollment for 2015. , According to Zane Benefits, ... in November, employees are encouraged to start thinking about ... 2015, the open enrollment period will run from November ... 2015 individuals can purchase a new individual health insurance ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... , , WESTBURY, N.Y., July ... in the Ophthalmic Consultants of Long Island (OCLI) practice will perform ... of sight to those who have lost some or all of ... Cataract USA program, is offering this outpatient surgical procedure to residents ...
... , , , HOUSTON, ... , , If you would like to learn ... Texas Health Institute as they host a morning-long forum on "Building a Federal ... The event will be held at St. Joseph Medical Center, 1401 St. ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... financial results for the second quarter ended June 30, 2009 on ... , , NxStage will also host ... 5, 2009 to discuss its second quarter financial results. To listen ...
... , , WALTHAM, Mass., ... and advisory firms focusing on pharmaceutical and healthcare issues, finds that ... million in 2008 to more than $315 million in 2013. The ... Humira and Schering-Plough,s Remicade which recorded sales of $50 million and ...
... , , BANNOCKBURN, Ill., July ... in the United States(1). Yet it,s often not until the untimely passing ... or Tim Russert - that the issue is brought to the forefront ... heightened focus on heart health, a recent survey(2) uncovered that only 14 ...
... on intelligence tests at age 5 , MONDAY, July ... of a common airborne pollutant compound seems to threaten ... , The finding is based on the experience of ... City area. Specifically, it indicates that high prenatal exposure ...
Cached Medicine News:Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 3Health News:Building a Federal Health Board - Impact on Texas 2Health News:NxStage to Report Second Quarter 2009 Financial Results 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Exposure to Common Pollutant in Womb Might Lower IQ 2Health News:Exposure to Common Pollutant in Womb Might Lower IQ 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: